Neurokinin Receptor Antagonists: Broad Therapeutic Potential Beyond Anti-Nausea Use
Despite the tachykinin system's involvement in cancer, pain, itch, obesity, and more, only five NK-1 receptor antagonists are approved — all for nausea — leaving vast therapeutic potential untapped.
Quick Facts
What This Study Found
Only 5 NK-1R antagonists are clinically approved (all for emesis) despite the tachykinin system's involvement in cancer, pain, itch, obesity, and numerous other conditions — representing significant therapeutic underexploration.
Key Numbers
5 approved NK-1R antagonists; 0 NK-2R/NK-3R approved; patents cover: cancer, pruritus, cardiomyopathy, respiratory, infection, eye, weight, fear, hot flashes, reproduction
How They Did This
Patent review covering NK receptor antagonist inventions and clinical applications from 2014 to 2020.
Why This Research Matters
Blocking neuropeptide signaling through NK receptors could treat conditions from cancer to chronic itch, but these drugs remain almost exclusively used for nausea — a missed therapeutic opportunity.
The Bigger Picture
The gap between the broad biological roles of tachykinin neuropeptides and the narrow clinical use of their antagonists represents one of the larger missed opportunities in neuropeptide-based medicine.
What This Study Doesn't Tell Us
Patent review format — focuses on inventions rather than clinical evidence strength; many proposed applications remain preclinical; reasons for limited clinical translation not fully analyzed.
Questions This Raises
- ?Why have NK receptor antagonists failed to gain approval beyond anti-emetic indications?
- ?Could NK-1R antagonists like aprepitant be repurposed for cancer or chronic itch?
- ?Will NK-3R antagonists ever reach approval for hot flashes or reproductive disorders?
Trust & Context
- Key Stat:
- Only 5 approved, all for nausea Despite NK receptor involvement in cancer, pain, itch, obesity, and dozens more conditions
- Evidence Grade:
- Patent review providing broad overview but limited evidence assessment; most proposed therapeutic applications lack robust clinical trial data.
- Study Age:
- Published in 2020; NK-3 receptor antagonists for hot flashes (like fezolinetant) have since advanced toward approval.
- Original Title:
- Neurokinin receptor antagonism: a patent review (2014-present).
- Published In:
- Expert opinion on therapeutic patents, 30(7), 527-539 (2020)
- Authors:
- Muñoz, Miguel(5), Coveñas, Rafael(2)
- Database ID:
- RPEP-05019
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are neurokinin receptor antagonists used for?
Currently only approved for nausea prevention (anti-emetics), but research suggests they could treat cancer, chronic itch, pain, obesity, and many other conditions involving tachykinin neuropeptides.
Why are substance P blockers not used for more conditions?
Despite strong preclinical evidence, NK receptor antagonists have not been adequately tested in clinical trials for most potential applications, limiting their approved uses to nausea.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05019APA
Muñoz, Miguel; Coveñas, Rafael. (2020). Neurokinin receptor antagonism: a patent review (2014-present).. Expert opinion on therapeutic patents, 30(7), 527-539. https://doi.org/10.1080/13543776.2020.1769599
MLA
Muñoz, Miguel, et al. "Neurokinin receptor antagonism: a patent review (2014-present).." Expert opinion on therapeutic patents, 2020. https://doi.org/10.1080/13543776.2020.1769599
RethinkPeptides
RethinkPeptides Research Database. "Neurokinin receptor antagonism: a patent review (2014-presen..." RPEP-05019. Retrieved from https://rethinkpeptides.com/research/munoz-2020-neurokinin-receptor-antagonism-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.